Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 3, 325-330, March 2007; doi:10.1634/theoncologist.12-3-325
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sequist, L. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sequist, L. V.

Lung Cancer

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Lecia V. Sequist

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Key Words. Epidermal growth factor receptor • Non-small cell lung cancer • Tyrosine kinase

Correspondence: Lecia V. Sequist, M.D., M.P.H., Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA. Telephone: 617-726-7812; Fax: 617-726-0453; e-mail: lvsequist{at}partners.org

Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. Ichihara, K. Ohashi, N. Takigawa, M. Osawa, A. Ogino, M. Tanimoto, and K. Kiura
Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
Cancer Res., June 15, 2009; 69(12): 5091 - 5098.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Newer Cytotoxic Agents: Attacking Cancer Broadly
Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
PNAS, February 12, 2008; 105(6): 2070 - 2075.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement